The International Consensus of Classification of myelodysplastic syndromes and related entities (2022) introduces the multi-hit status, defined by either two TP53 mutations (each with VAF > 10%) or one mutation (VAF > 10%) accompanied by the following: (1) a deletion involving the TP53 locus at chromosome 17p.31, (2) VAF > 50%, or (3) copy-neutral LOH at 17p. The gene discussed is TP53; the disease is myelodysplastic syndrome.